The identification of effective treatments for neurodegenerative diseases is a ‘holy grail’ of drug development, where complex biological systems and long regulatory timelines conspire to leave many drug candidates on the cutting room floor. Major bottlenecks in the field include poorly understood mechanisms of neuron pathology, limited clinical or diagnostic biomarkers, and model organisms with little predictive value to their human counterparts. This intellectual property portfolio from Stanford includes tools to help solve some of these persistent problems across drug development in neurodegenerative diseases, including novel targets against conditions like Huntington’s diseases, Alzheimer’s, and Parkinson’s.